Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. - Wikidata - wikimedia - TriplyDB

Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus.

Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus.

http://www.wikidata.org/entity/Q37280337

about

Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery A holistic approach to targeting disease with polymeric nanoparticles Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission Synthetic Nanoparticles for Vaccines and Immunotherapy Particle tracking in drug and gene delivery research: State-of-the-art applications and methods Genital Herpes: Insights into Sexually Transmitted Infectious Disease A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue.Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation.Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth.Nanoparticle-based drug delivery to the vagina: a review.Controlled release for local delivery of drugs: barriers and models.Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse.Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.Liposome-based mucus-penetrating particles (MPP) for mucosal theranostics: demonstration of diamagnetic chemical exchange saturation transfer (diaCEST) magnetic resonance imaging (MRI).Hyaluronan in cervical epithelia protects against infection-mediated preterm birth.Enema ion compositions for enhancing colorectal drug delivery.Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles.Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.Chitosan and Kappa-Carrageenan Vaginal Acyclovir Formulations for Prevention of Genital Herpes. In Vitro and Ex Vivo Evaluation.Effect of Mucosal Cytokine Administration on Selective Expansion of Vaginal Dendritic Cells to Support Nanoparticle Transport.Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination Nanoparticle diffusion in respiratory mucus from humans without lung disease.Biomaterial Strategies for Immunomodulation.PEGylation as a strategy for improving nanoparticle-based drug and gene delivery Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo.Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues.Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake.Magnetic Nanodrug Delivery Through the Mucus Layer of Air-Liquid Interface Cultured Primary Normal Human Tracheobronchial Epithelial Cells.Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.Diamond nanogel-embedded contact lenses mediate lysozyme-dependent therapeutic release.Engineering synthetic vaccines using cues from natural immunity.Strategies for improving mucosal drug delivery.Cancer nanomedicine: from drug delivery to imaging.Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.Engineering immunity in the mucosal niche against sexually transmitted infections.Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination.

P2860

Q26823541-466AAF71-EF1E-4AD9-98E6-8AE4BE20C91A Q26865163-E4678355-11CB-4716-BE9C-10DF6A731E22 Q27318354-9C7E4E02-E7D6-4FC3-BAEB-E9F9532D5571 Q28085375-10BF955D-E0F7-4F11-9128-B6C76FBCA008 Q28087396-1FCB27A8-D6A6-4BF5-90F5-44701D30B787 Q30235026-2615F1E0-E47F-4BAF-96B6-783859C86F53 Q30431343-DAD14E8D-5647-4A57-A1F1-ED9FDBB4BC58 Q30541682-DB8DFB4E-E439-434B-83AC-F13E4493F679 Q30844270-70D4419D-D205-4F9C-B5BD-3361D4E4133E Q33763847-E7D388B2-4218-4981-925E-88D3CBF17E2E Q34079533-CB7975E0-26D1-40C2-9427-06F5DD4A032A Q34079560-0D112AE8-E99F-4CC4-9CE7-3E57CC0A032B Q34669705-41AC5091-379E-46E5-9C9A-CA3459037B45 Q34749181-0B64E8D5-83D2-4C21-B87D-7A1FE0EE6AB0 Q34785621-A752A2C1-92AF-45BF-BE61-AE86210C312A Q35088353-4DA33AB5-6192-445E-A464-37B1DCEEF0A1 Q35145380-077EDFCF-258F-4296-B32C-4EAC89813E88 Q35691007-D1BACB3A-DF16-4C79-9945-31A3E3568D93 Q35759073-CD7B7FAF-EF47-44FE-AEBD-9158A5D28D0F Q35947035-2420E21A-FD84-4227-9E9B-4DE5D1147DB3 Q36096590-C769944B-4FC9-4ADC-AC7C-2DE2661E455F Q36143091-90AA8139-2031-4D3A-B307-085A7B99527F Q36442232-88264C2E-97A9-49B2-A803-D128E73B8D9F Q36509826-72AF6455-3440-4824-B9A9-CC22D9CA3081 Q36664260-7301794E-6EFA-4819-880E-6D5679C7251D Q36703124-FED7314B-0183-4D19-98DC-AE61A27AFC4B Q36703361-DFD656E9-B2B9-4CF0-A9A6-6A3F63DA1782 Q36961634-78532D9C-CA06-4F6B-A821-0C031727CF69 Q37011581-CDAE8DAC-0E3D-40AA-8725-DFA22D97E02A Q37062353-6C479D84-381D-4E1F-8312-3F222F022211 Q37158237-DD197FBA-4CDE-404B-BB4A-2A943720BBD4 Q37350756-0A3CD723-A3FE-43FC-9B11-B1DAF809AF71 Q37358616-03DADC5C-EAB2-4F7F-8DAC-D19E0377F397 Q37731617-7F003CD7-6459-420A-A3BB-1048B16E7342 Q38154804-5AF5013A-3F65-4CFF-BACC-29AE7CAB5375 Q38166442-DAB0996B-BC1A-42DA-88D5-B4D005F3CA80 Q38172476-9506A529-D984-4B96-BDFF-78A33CF8D456 Q38260862-B45A4729-D94C-4BF7-93E3-50F08D5B3AC0 Q38543768-6CD7EAB6-2C42-4782-8379-4C5B1EAA9C84 Q38702368-BE8983A4-BFEF-4BB5-8766-BEDBFFC80198

P2860

Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus.

http://www.wikidata.org/entity/Q37280337

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Mucus-penetrating nanoparticle ...... against herpes simplex virus.

@en

Mucus-penetrating nanoparticle ...... against herpes simplex virus.

@nl

type

label

Mucus-penetrating nanoparticle ...... against herpes simplex virus.

@en

Mucus-penetrating nanoparticle ...... against herpes simplex virus.

@nl

prefLabel

Mucus-penetrating nanoparticle ...... against herpes simplex virus.

@en

Mucus-penetrating nanoparticle ...... against herpes simplex virus.

@nl

P1433

Q37280337-966A0407-B47A-48D2-81CA-5E55CC178544

P1476

Q37280337-E0E7F9C3-2804-4F79-9D38-9B706C2B4BD0

P2093

Q37280337-74C0DCE5-A40B-41CB-A87C-ADE00A8D3EE5

Q37280337-7EAF8DF0-3CDB-4B78-B69E-E82CAF9FDCDD

Q37280337-8928017F-6C4B-4070-B044-C90D34765F16

Q37280337-95B43076-C681-443F-9266-9DEF045FA1C0

Q37280337-BF701B52-3996-4B8F-B77D-4EFE1B2FFD2B

Q37280337-C606AAA6-B226-4F97-8F68-B75E94D15029

P2860

Q37280337-0552B262-CBF8-4A5E-8253-4E43790000DF

Q37280337-0710AAE1-BBBE-4EC3-BE16-7C6784A45075

Q37280337-1120A35E-42ED-46CE-A726-CE0DD8DCDB7C

Q37280337-2AEE52E7-1764-46FB-97B4-EFB3D41A3590

Q37280337-2EF5C3E0-43A2-44B1-8488-342AAE6AA4EB

Q37280337-2F67A227-9707-4D40-919D-24C86843EB2B

Q37280337-3C2B6AB4-EF0F-4949-B116-8E30EABF4C7B

Q37280337-3EA96507-6B7D-4D7B-8BFB-D5D5F7231B1F

Q37280337-41FFDB2A-5E3D-4446-8D9F-37F2CE53B2F9

Q37280337-42DB036B-C4EE-4871-B904-4407C4DA0C0F

P304

Q37280337-4FF14331-0D13-4DE6-9F97-946AD7CAA31F

P31

Q37280337-7E305135-B0D0-414A-9D51-5393DDCD6473

P356

Q37280337-CA5FF601-7C40-4CAE-9BFD-3C059F0716FF

P407

Q37280337-66447325-6631-4650-ACA7-43438BF59AA5

P433

Q37280337-9FC8F756-33FC-45D7-B123-484101BA9514

P478

Q37280337-B9B8109B-028D-47CB-BF7D-2EBD2DDC6254

P50

Q37280337-3303732C-8651-46D0-A61A-9AA2DBD4FF38

P577

Q37280337-77D9BF09-921F-4D8C-AB1E-7A663D5C0A2E

P698

Q37280337-A0FF3A17-027B-444A-A705-7AD509DAF710

P921

Q37280337-013F0FC3-3AFB-4938-80E0-C676D5D3B117

Q37280337-82829B1F-A45F-4ACF-A335-A99B38512100

P932

Q37280337-54100BA1-129D-43F4-B642-07BF1CE62325

P356

SCITRANSLMED.3003453

P1433

Science Translational Medicine

P1476

Mucus-penetrating nanoparticle ...... against herpes simplex virus.

@en

P2093

Benjamin C Tang

http://www.w3.org/2001/XMLSchema#string

Laura M Ensign

http://www.w3.org/2001/XMLSchema#string

Richard Cone

http://www.w3.org/2001/XMLSchema#string

Terence A Tse

http://www.w3.org/2001/XMLSchema#string

Timothy Hoen

http://www.w3.org/2001/XMLSchema#string

Ying-Ying Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide

A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections

Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus.

Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus.

The exfoliating cervico-vaginal surface. II. Scanning electron microscopical studies during the estrous cycle in mice.

Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission

Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses.

Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse.

Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.

P304

138ra79

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3003453

http://www.w3.org/2001/XMLSchema#string

P407

P433

138

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22700955

http://www.w3.org/2001/XMLSchema#string

P921

P932

3817739

http://www.w3.org/2001/XMLSchema#string